Trial Profile
A Randomized Comparison of a Sirolimus-eluting Stent With Biodegradable Polymer Versus an Everolimus-eluting Stent With a Durable Polymer for Percutaneous Coronary Revascularization
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Everolimus
- Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Myocardial infarction; Thrombosis
- Focus Therapeutic Use
- Acronyms BIOSCIENCE
- 19 Sep 2022 Results of Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized Trials presented at the Transcatheter Cardiovascular Therapeutics 2022
- 17 Feb 2021 Results of a meta-analysis from five clinical studies: NCT01356888, NCT01939249, NCT02389946, NCT01443104 and NCT02579031 published in the American Heart Journal
- 01 Sep 2020 Results (n=1131) of sub-group analysis 5-year outcomes in patients with acute coronary syndrome, presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology.